Clinical Evidence Strategy for EU MDR Compliance

Clinical evaluation under EU MDR is the systematic and ongoing process of assessing clinical data to verify a device's safety, performance, and clinical benefits for its intended purpose. It typically includes literature review, appraisal of relevant data, analysis of post-market information, and documented conclusions in a Clinical Evaluation Report. The process must be methodologically sound, current, and aligned with the device's risk profile.

A clinical evaluation starts with defining the device scope, intended purpose, and applicable claims. From there, manufacturers identify relevant clinical data sources, appraise the quality and relevance of evidence, analyze safety and performance outcomes, and document conclusions in the CER. Under EU MDR, the evaluation must also connect with risk management, PMS, PMCF, and technical documentation to form a coherent regulatory justification.

Manufacturers should define a clinical evidence strategy as early as possible, ideally before major testing plans, CER drafting, or Notified Body engagement. It is especially important for higher-risk devices, implantables, novel technologies, and products relying on equivalence. Early strategy work helps determine whether existing literature is sufficient, whether PMCF can close gaps, or whether a clinical investigation may be needed.

A strong strategy defines the right mix of evidence sources for the device, such as published literature, PMCF outputs, complaint and PMS data, clinical investigations, and real-world evidence. It also addresses equivalence viability, residual risk justification, benefit-risk conclusions, and how evidence will support the CER, SSCP where applicable, and GSPR conformity. The goal is a traceable, defensible evidence framework rather than disconnected documents.

Sometimes, but not always. Literature may be sufficient for lower-risk, well-established devices with strong published evidence and limited novelty. However, EU MDR often requires broader support, especially where equivalence is weak, claims are ambitious, or post-market data is limited. Manufacturers frequently need a combination of literature, PMCF, and device-specific data to satisfy Notified Body expectations and justify safety and performance conclusions.

PMCF is a core part of the ongoing clinical evaluation lifecycle under EU MDR. It helps confirm continued safety and performance in real-world use, identify emerging risks, and address residual uncertainties that premarket evidence alone may not resolve. A sound clinical evidence strategy defines whether PMCF is required, what methods are proportionate, and how PMCF outputs will feed back into the CER, PMS reports, and risk management updates.

Common issues include weak literature search methodology, unsupported equivalence claims, outdated CERs, poor linkage between clinical conclusions and risk management, inadequate PMCF rationale, and inconsistent technical documentation. Notified Bodies also scrutinize whether evidence actually supports the intended purpose and claims. Addressing these gaps early through a structured review can prevent deficiency cycles, rework, and avoidable delays in CE marking timelines.

The timeline depends on device complexity, evidence maturity, and document quality, but a focused readiness assessment can often begin quickly once core files are available. Reviews typically examine CER content, literature methods, PMCF adequacy, risk management linkage, and technical file consistency. The output should be a prioritized action plan so teams know which evidence gaps are critical before engaging a Notified Body.